Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2020-07-16 Director's Dealing
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Director Dealings and Issue of Equity
Director's Dealing Classification · 100% confidence The document is an RNS announcement detailing the exercise of stock options and subsequent sale of shares by the CEO and CFO of MaxCyte, Inc. It explicitly includes the 'Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities' (PDMR) tables. This falls directly under the 'Director's Dealing' category, as it reports personal share transactions by company executives.
2020-07-16 English
Trading Update
Regulatory Filings Classification · 98% confidence The document is a 'Trading Update' issued by MaxCyte, Inc. via the London Stock Exchange's RNS (Regulatory News Service). It provides key financial highlights (revenue growth, financing, and operational updates) for the first half of the year, ahead of the formal interim results. According to the filing definitions, an initial announcement of quarterly/periodical financial results (key highlights only) is classified as an Earnings Release (ER).
2020-07-15 English
APEIRON Biologics Clinical and Commercial License
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a new clinical and commercial licensing agreement between MaxCyte, Inc. and APEIRON Biologics. Since this is a corporate announcement regarding a business partnership/licensing deal that does not fit into specific categories like M&A (which usually implies a merger or acquisition of the company itself) or other specialized financial reports, it falls under the general regulatory announcement category.
2020-07-08 English
Block Listing Return & TVR
Regulatory Filings Classification · 98% confidence The document is an 'AIM Block Admission Return' filed via the London Stock Exchange's RNS (Regulatory News Service). It details the status of shares issued under a specific incentive plan and provides the total issued share capital. While it mentions share-related data, it is a standard regulatory disclosure regarding block admission and total voting rights, which falls under the RNS (Regulatory Filings) category as it is a routine regulatory announcement rather than a specific share issuance or repurchase event.
2020-07-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for shareholders to disclose when their voting rights in a company cross certain thresholds. This is a classic 'Major Shareholding Notification' (MRQ) filing, as it details the identity of the shareholder (Unicorn Asset Management Limited), the issuer (MaxCyte, Inc.), and the change in voting rights percentage.
2020-06-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. This is a regulatory requirement for shareholders to disclose when their ownership interest in a company crosses specific thresholds. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2020-05-28 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.